Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData

This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)

Global Digital Health Summit outlines roadmap for making India a global leader in digital health implementation

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials

Global health challenges can be resolved using digital technology: Dr Alain Labrique

Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis

Meningitis still affects more than 2.5 million people globally each year

USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine

The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Global Hospitals Parel Mumbai completes 100 successful robotic surgeries

The 100 surgeries conducted using robotic technology span various intricate procedures in the fields of Urology, Liver Transplantation, GI surgery, Cardiac surgeries and Gynaecology

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers